卡培他滨治疗晚期肾癌32例临床观察  

Clinical observation of capecitabine in treating 32 patients with metastatic renal cancer

作　　者：马蕾[1] 韩忠诚[1] 柳江[1] 

机构地区：[1]新疆自治区人民医院肿瘤内科,新疆乌鲁木齐830001

出　　处：《现代肿瘤医学》2012年第11期2357-2358,共2页Journal of Modern Oncology

摘　　要：目的:观察卡培他滨治疗晚期肾癌的疗效及不良反应。方法:经影像学诊断的晚期肾癌32例,使用卡培他滨2000mg/m2,分2次口服,d1-14,每3周1个周期,至少用4周期以上评价疗效。结果:32例均可评价疗效,CR 0例,PR 7例,总有效率21.9%(7/32)。主要不良反应为恶心、呕吐、手足综合征、骨髓抑制及腹泻,无化疗相关死亡。结论:卡培他滨治疗晚期肾癌有一定疗效,不良反应可以耐受,值得深入研究。Objective：To evaluate the clinical effect and toxicity of capecitabine in the treatment of metastatic renal cancer.Methods：All 32 patients with metastatic renal cancer diagnosed by imageology were treated with capecitabine 2000mg/m^2 twice daily orally on day 1-14.The regimen was repeated every 21 days at least four cycles.Results：Of 32 patients complete remission（CR） was observed in 0 case and PR in 7 cases,the total response rate was 21.9%（7/32）.The main side effects were myelosuppression,diarrhea,hand-foot syndrome and nausea /vomiting.There were no any death events during treatment.Conclusion：Capecitabine in the treatment of metastatic renal cancer is effective and tolerable.

关 键 词：肾癌 卡培他滨 治疗 

分 类 号：R737.1[医药卫生—肿瘤]